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Quiescent fibroblasts derived from human fetal lung can be stimulated to reinitiate DNA synthesis by sequential addition 
of 3 nM IGF- 1 and a low concentration (8 PM) of EGF or by continuous exposure to 10% fetal calf serum or 10 ng/ml 
PDGF. Bradykinin blocks the IGF-1 and EGF-dependent signals without affecting the response to serum or PDGF. 
It activates protein kinase C and its anti-mitogenic effect is abolished after this kinase has been down-regulated. Bradykin- 
in has no effect on the binding affinity of the EGF receptor whereas phorbol ester induces its ‘transmodulation’ to low 
atfinity. 
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1. INTRODUCTION 
Early intracellular events in the triggering of a 
growth factor-dependent proliferative program 
have been well documented. They include activa- 
tion of tyrosine kinase activities intrinsic to some 
growth factor receptors [l], activation of 
phosphatidylinositol breakdown [2] and protein 
kinase C [3] and fluxes of several ions e.g. H+ [4] 
and Ca” [5]. Identification of events specific to 
one pathway but not another has been less suc- 
cessful. In mouse BALB/c-3T3 cells [6,7] it has 
been shown that prior exposure to PDGF is re- 
quired before EGF or a combination of EGF and 
IGF-1 can commit the cells to DNA synthesis and 
division. In human diploid fibroblasts, on the 
other hand, it appears that either PDGF or EGF 
will suffice to initiate cell division [8], indicating 
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Human fetal lung fibroblasts (Flow Laboratories) were 
cultured in a 1: 1 mixture of DMEM and Ham’s F12 nutrient 
mixture, supplemented with 10% fetal calf serum, 50 U.ml-’ 
penicillin and 50 cg .ml-’ streptomycin. Exponentially growing 
cultures (passages 15-20) were starved in 0.1% serum for 
36-48 h to obtain subconfluent, quiescent cells. 
Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium; 2.3. Time-lapse cinematography 
EGF, epidermal growth factor; PDGF, platelet-derived growth A culture flask containing 5000-6000 starved cells-cm-’ and 
factor; IGF-1, insulin-like growth factor 1; TPA, 12-0- 10 ml of medium (0.1% serum) with appropriate additions was 
tetradecanoylphorbol 13-acetate placed in an airstream incubator on an inverted microscope 
that cellular responses to combinations of growth 
factors may be specific to the cell type and/or its 
culture history. In the present work we have 
observed synergy between EGF and IGF-1 in the 
human system and examined the action of 
bradykinin in discriminating between IGF-1 /EGF- 
dependent and PDGF-dependent pathways. 
2. MATERIALS AND METHODS 
2.1. Growth factors 
IGF-1 (recombinant) was from Amersham International 
(England) and EGF from Collaborative Research (USA). 
PDGF was a gift from Dr C.-H. Heldin. 
2.2. Cell culture 
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equipped with a video camera and a time-lapse video recorder. bradykinin or 150 nM TPA were added for 2 h at 37’C before 
A field of about 50 well-separated cells was chosen and one pic- rinsing the plates with ice-cold binding buffer (Earle’s balanced 
ture was recorded every minute. No significant cell death was salts solution buffered with 20 mM Hepes and containing 0.1% 
observed during the experiment. Cell division was scored as the bovine serum albumin). 16 pM ‘%EGF and O-100 nM 
completion of the division furrow between a pair of cells. In ex- unlabeled EGF were added in 2 ml buffer and allowed to 
periments where protein kinase C was down-regulated, 150 nM equilibrate with the cells for 9 h at 4°C. The cells were washed 
TPA was added to the medium during the starvation period. and then dissolved in 1 M NaOH overnight and the radioactivi- 
Growth factor regimes were either 10 ng/ml PDGF + 100 nM ty counted. Non-specific binding (in the presence of 100 nM 
bradykinin or 3 nM IGF-1 given for 4 h, washed out and unlabeled EGF) was about 5% of total binding. Data were 
replaced with 8 pM EGF + 100 nM bradykinin. analysed using the LIGAND computer program [9]. 
2.4. Thymidine uptake 2.6. Two-dimensional gel electrophoresis 
Cells were seeded into 24well plates and starved to 
quiescence when still subconfluent. 22 h after the initiation of 
the treatment with growth factors (as above) the medium was 
replaced with 1 ml of DMEM containing 2 &i [3H]thymidine 
(56 Ci .mmol-I). After a further 12 h, the cells were rinsed and 
then fixed in methanol/acetic acid (3 : 1) for 1 h, washed in 
distilled water and allowed to dry in air. The wells were coated 
with a 1: 1 dilution of Ilford K2 emulsion in water at 45’C. Ex- 
cess emulsion was aspirated and the plates dried over silica gel 
at room temperature for 24 h before storage at 4°C for 3-6 
days. Development was by standard photographic techniques. 
2.5. EGF binding assays 
“‘1-EGF was prepared by the iodogen (Pierce) method and 
purified on a Waters Cis SepPak cartridge. Fibroblasts were 
grown in 50 mm dishes and starved as above. 100 nM 
Starved (and in some cases, TPA-treated) cultures in 35 mm 
dishes were incubated for 4 h at 37°C with 1 ml Hepes-buffered 
phosphate-free DMEM containing 200 pCi [“Plorthophos- 
phate. 15 min before the end of this period, they were treated 
with 100 nM bradykinin or 150 nM TPA. The medium was 
removed and the cells washed rapidly with ice-cold phosphate- 
buffered saline. They were then dislodged by scraping into 
200~1 ice-cold lysis buffer (20 mM Hepes, 50 mM benxami- 
dine, 10 mM EDTA, 100 mM NaF, 5 mM 2-mercaptoethanol, 
10,uM sodium orthovanadate, 1% Triton X-100, pH 7.4), 
vortexed vigorously and centrifuged. Sample preparation and 
electrophoresis were essentially as described [lo]. 30 ,ug of pro- 
tein were loaded onto each iso-electric focusing gel (1.6% pH 
4-6, 0.4% pH 3-10 LKB-Ampholines). Electrophoresis in the 
second dimension was on 10% acrylamide gels in the presence 
of SDS. 
mitoses er 
1000 ce f 1s 
hours 
mitoses per 
1000 cells 
r 0 
200 - 
100 - 
i 
I F-J 
k 24 36 
hours 
Fig. 1. Time-lapse cinematography. Video recording was started at the beginning of the treatment regime. (A) Effects of serum and 
PDGF: (&--A) 0.1% serum; (a) 10% serum; (O--O) PDGF; (0) PDGF + bradykinin. (B) Effects of IGF-1, EGF and 
bradykinin: (C--O) IGF-1; (a) IGF-1 + EGF; (ti) IGF-1 + EGF + bradykinin. 
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3. RESULTS AND DISCUSSION 
PDGF or 10% serum both induced a mitotic 
response in quiescent cells after a lag period of 
about 28 h (fig.lA) and further addition of 
bradykinin was without effect. The sequential 
combination of IGF-1 and 8 pM EGF caused a 
small wave of mitosis after 8 h and a second larger 
wave after 24-26 h (fig. 1B). IGF-1 alone had only 
marginal effect. Bradykinin abolished both waves 
of mitosis. The early response to IGF-l/EGF 
needs further work to assess its provenance but 
distinguishes this cellular response from that to 
PDGF or serum. 
We confirmed the action of bradykinin on cell 
division by assaying DNA synthesis. 10% serum 
caused a lo-fold increase in nuclear labeling by 
[3H]thymidine (fig.2). The IGF-l/EGF combina- 
tion, but neither factor given alone, elicited a 
strong response, which was abolished by 
bradykinin. 
The specific binding of 16 pM lz51-EGF to 
bradykinin-treated cells was not significantly dif- 
ferent from control (96%) whereas binding to 
TPA-treated cultures was markedly reduced (60% 
of control, mean of three experiments). Computer 
analysis revealed the binding curves to have both 
high and low affinity phases (dissociation con- 
Fig.2. [“H]Thymidine uptake and its response to growth 
factors. The results represent the means (f SE) of 
quadruplicate stimates of the percentage of cell nuclei labeled 
with [‘Hlthymidine. 
stants of 40-100 pM and 8-12 nM, respectively) 
for the control and bradykinin-treated cells but 
that only low affinity sites remained after TPA 
treatment. We conclude that TPA causes the well- 
documented transmodulation of the EGF receptor 
to low affinity [ll] but that bradykinin under our 
conditions does not. This rules out a reduction by 
bradykinin of the occupancy of the EGF receptor 
(in the presence of the low concentration of EGF) 
as the basis of its anti-mitogenic effect. 
This effect was found to be dependent on pro- 
tein kin&e C activity. In cells whose kinase levels 
had been down-regulated by exposure to 150 nM 
TPA over 48-60 h bradykinin increased the 
number of cells entering mitosis and shortened the 
time required to reach maximal mitotic activity 
(fig.3). Whether this results from a loss of a nor- 
mal damping action of protein kinase C is unclear. 
TPA was still mitogenic under these conditions, 
suggesting the persistence of some protein kinase C 
activity, but insufficient to mediate any inhibitory 
response to bradykinin. 
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Fig.3. Time-lapse cinematography after down-regulation of 
protein kinase C. (M) TPA; (A--A) IGF-1 + EGF; 
(A-4) IG-1 + EGF + bradykinin. 
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Fig.4. Two. -dimensional gel electrophoresis of “P-labeled cells. (A) Autoradiogram from a control sample. The position of the 87 kDa 
spot is indi cated by an arrow and the corner cut out for part B outlined. (B) The 87 kDa region of gels from experiment :a1 samples. 
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We assayed the protein kinase C activity more 
directly by comparing the cellular protein 
phosphorylation patterns produced by bradykinin 
or TPA. An acidic phosphoprotein of approximate 
molecular mass 87 kDa can be readily resolved by 
two-dimensional electrophoresis and is believed to 
be a substrate for protein kinase C in vivo [12,13]. 
In its stimulation of ‘87K’ phosphorylation in con- 
trol, but not in chronically TPA-treated cells, 
bradykinin was indistinguishable from TPA 
(fig.4). It is clear that it must activate at least some 
subclasses of protein kinase C. 
Our results on the IGF-l/EGF synergy are not 
peculiar to lung fibroblasts and our first observa- 
tions of this phenomenon were during studies on 
human embryonic cornea1 fibroblasts [14]. This 
particular mitogenic pathway can be distinguished 
from that employed by serum or PDGF by its dif- 
ferent timing pattern and its sensitivity to 
bradykinin. 
The reported effects of activators of protein 
kinase C on EGF-induced DNA synthesis have 
been contradictory. In mouse 3T3 cells, TPA and 
EGF act synergistically [15] but in human 
fibroblasts TPA antagonizes the action of EGF 
[la]. Our results are consistent with the latter 
report. 
In the light of recent observations of many 
subclasses of protein kinase C [ 171, some of which 
have been demonstrated to show differing ac- 
tivities toward the EGF receptor [18], we suggest 
that bradykinin activates species of this enzyme 
which can phosphorylate the 87 kDa protein and 
interfere with EGF-, but not PDGF-stimulated 
mitosis, but cannot cause transmodulation of the 
EGF receptor. Whether they can phosphorylate 
the EGF receptor is still an open question since 
there are a number of candidate substrate sites on 
that molecule, in addition to the Thr-654 residue 
which has been implicated in transmodulation 
[19]. Other possibilities are that these protein 
kinase species act at other loci specific to the EGF 
pathway, an avenue we are currently pursuing, or 
that intracellular release of inositol trisphosphath 
[2] may be responsible for the constellation of ef- 
fects reported here. 
Acknowledgements: E.L.N. is grateful to Dr Gilles L’Allemain 
and Dr Jacques Pouyssegur (Nice, France) in whose laboratory 
he held a short-term EMBO fellowship to learn the elec- 
trophoretic technique. We thank Dr Louis Mahadevan for 
critical reading of an early version of the manuscript. L.H. held 
a fellowship from the International Federation of University 
Women. The financial support of the Barn Cancerfonden, the 
Swedish Society of Medicine, the O.E. & Edla Johanssons 
Foundation, the Carmen & Bertil Regners Foundation and 
EMBO is gratefully acknowledged. 
REFERENCES 
111 
121 
[31 
141 
PI 
WI 
[71 
PI 
191 
UOI 
1111 
WI 
[I31 
[I41 
WI 
1161 
1171 
WI 
u91 
Hunter, T. and Cooper, J.A. (1985) Annu. Rev. 
Biochem. 54, 897-930. 
Berridge, M.J. and Irvine, R.F. (1984) Nature 312, 
315-321. 
Nishizuka, Y. (1984) Science 225, 1365-1370. 
Moolenaar, W.H., Tsien, R.Y ., Van der Saag, P.L. and 
De Laat, S.W. (1983) Nature 304, 645-648. 
Moolenaar, W.H., Aerts, R.J., Tertoolen, L.G.J. and De 
Laat, S.W. (1986) J. Biol. Chem. 261, 279-284. 
Pledger, W.J., Stiles, C.D., Antoniades, H.N. and Scher, 
C.D. (1978) Proc. Natl. Acad. Sci. USA 75, 2839-2843. 
Leaf, E.B., Wharton, W., Van Wyk, J.J. and Pledger, 
W.J. (1982) Exp. Cell Res. 141, 107-115. 
Westermark, B. and Heldin, C.-H. (1985) J. Cell. 
Physiol. 124, 43-48. 
Munson, P.J. (1983) Methods Enzymol. 92, 543-576. 
Blackshear, P.J., Nemenoff, R.A. and Avruch, J. (1982) 
Biochem. J. 204, 817-824. 
King, A.C. and Cuatrecasas, P. (1982) J. Biol. Chem. 
257, 3053-3060. 
Blackshear, P.J., Wen, L., Glynn, B.P. and Witters, 
L.A. (1986) J. Biol. Chem. 261, 1459-1469. 
Albert, K.A., Nairn, A.C. and Greengard, P. (1987) 
Proc. Natl. Acad. Sci. USA 84, 7046-7050. 
Hyldahl, L. (1986) PhD Thesis, Karolinska Institute, 
Stockholm, Sweden. 
Dicker, P. and Rozengurt, E. (1980) Nature 287, 
607-612. 
Decker, S.J. (1984) Mol. Cell. Biol. 4, 1718-1724. 
Nishizuka, Y. (1988) Nature 334, 661-665. 
Ido, M., Sekiguchi, K., Kikkawa, U. and Nishizuka, Y. 
(1987) FEBS Lett. 219, 215-218. 
Schlessinger, J. (1988) Biochemistry 27, 3119-3123. 
229 
